Trial Profile
Safety and efficacy of bendamustine plus melphalan conditioning regimen followed by autologous stem cell transplantation in patients with multiple myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2017
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 21 Dec 2017 New trial record
- 12 Dec 2017 Results assessing efficacy presented at the 59th Annual Meeting and Exposition of the American Society of Hematology